{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T01:34:12Z","timestamp":1789263252202,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,12,5]],"date-time":"2014-12-05T00:00:00Z","timestamp":1417737600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s00280-014-2643-1","type":"journal-article","created":{"date-parts":[[2014,12,4]],"date-time":"2014-12-04T07:44:48Z","timestamp":1417679088000},"page":"281-291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters"],"prefix":"10.1007","volume":"75","author":[{"given":"Jannick","family":"Clemens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Seckinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Theile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter Emil","family":"Haefeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Burhenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,5]]},"reference":[{"key":"2643_CR1","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","volume":"351","author":"RA Kyle","year":"2004","unstructured":"Kyle RA, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 351:1860\u20131873","journal-title":"N Engl J Med"},{"key":"2643_CR2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2141.2006.06271.x","volume":"135","author":"B Barlogie","year":"2006","unstructured":"Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J, Shaughnessy JD, Jagannath S, Bolejack V, Gurley J, Hoering A, Vesole D, Desikan R, Siegel D, Mehta J, Singhal S, Munshi NC, Dhodapkar M, Jenkins B, Attal M, Harousseau JL, Crowley J (2006) Longterm outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 135:158\u2013164","journal-title":"Br J Haematol"},{"key":"2643_CR3","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood-2011-09-379164","volume":"119","author":"K Neben","year":"2012","unstructured":"Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B, Salwender H, Blau IW, Weisel K, Pfreundschuh M, Scheid C, D\u00fchrsen U, Lindemann W, Schmidt-Wolf IG, Peter N, Teschendorf C, Martin H, Haenel M, Derigs HG, Raab MS, Ho AD, van de Velde H, Hose D, Sonneveld P, Goldschmidt H (2012) Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 119:940\u2013948","journal-title":"Blood"},{"key":"2643_CR4","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"PG Richardson","year":"2003","unstructured":"Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609\u20132617","journal-title":"N Engl J Med"},{"key":"2643_CR5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00280-010-1283-3","volume":"67","author":"DE Reece","year":"2011","unstructured":"Reece DE, Sullivan D, Lonial S, Mohrbacher AF, Chatta G, Shustik C, Burris H III, Venkatakrishnan K, Neuwirth R, Riordan WJ, Karol M, von Moltke LL, Acharya M, Zannikos P, Keith Stewart A (2011) Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemother Pharmacol 67:57\u201367","journal-title":"Cancer Chemother Pharmacol"},{"key":"2643_CR6","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00280-007-0424-9","volume":"60","author":"A Hemeryck","year":"2007","unstructured":"Hemeryck A, Geerts R, Monbaliu J, Hassler S, Verhaeghe T, Diels L, Verluyten W, van Beijsterveldt L, Mamidi RN, Janssen C, De Coster R (2007) Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14 C-bortezomib. Cancer Chemother Pharmacol 60:777\u2013787","journal-title":"Cancer Chemother Pharmacol"},{"key":"2643_CR7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jchromb.2013.01.037","volume":"926","author":"I Andriamanana","year":"2013","unstructured":"Andriamanana I, Gana I, Duretz B, Hulin A (2013) Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC\/MS\/MS. J Chromatogr B Anal Technol Biomed Life Sci 926:83\u201391","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"2643_CR8","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1358\/dot.2013.49.09.2020941","volume":"49","author":"P Puente de la","year":"2013","unstructured":"de la Puente P, Azab AK (2013) Contemporary drug therapies for multiple myeloma. Drugs Today (Barc.) 49:563\u2013573","journal-title":"Drugs Today (Barc.)"},{"key":"2643_CR9","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/leu.2010.129","volume":"24","author":"A Dispenzieri","year":"2010","unstructured":"Dispenzieri A, Jacobus S, Vesole DH, Callandar N, Fonseca R, Greipp PR (2010) Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial. Leukemia 24:1406\u20131411","journal-title":"Leukemia"},{"key":"2643_CR10","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1200\/JCO.2008.18.3087","volume":"27","author":"PG Richardson","year":"2009","unstructured":"Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi NC, Heffner LT, Doss D, Esseltine DL, Weller E, Anderson KC, Amato AA (2009) Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 27:3518\u20133525","journal-title":"J Clin Oncol"},{"key":"2643_CR11","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","volume":"112","author":"R Oerlemans","year":"2008","unstructured":"Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, Scheffer GL, Debipersad K, Vojtekova K, Lemos C, van der Heijden JW, Ylstra B, Peters GJ, Kaspers GL, Dijkmans BA, Scheper RJ, Jansen G (2008) Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 112:2489\u20132499","journal-title":"Blood"},{"key":"2643_CR12","doi-asserted-by":"crossref","first-page":"e56132","DOI":"10.1371\/journal.pone.0056132","volume":"8","author":"TB Shabaneh","year":"2013","unstructured":"Shabaneh TB, Downey SL, Goddard AL, Screen M, Lucas MM, Eastman A, Kisselev AF (2013) Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib. PLoS ONE 8:e56132","journal-title":"PLoS ONE"},{"key":"2643_CR13","first-page":"6174","volume":"63","author":"D Chauhan","year":"2003","unstructured":"Chauhan D, Li G, Shringarpure R, Podar K, Ohtake Y, Hideshima T, Anderson KC (2003) Blockade of Hsp27 overcomes Bortezomib\/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 63:6174\u20136177","journal-title":"Cancer Res"},{"key":"2643_CR14","doi-asserted-by":"crossref","first-page":"e20254","DOI":"10.1371\/journal.pone.0020254","volume":"6","author":"C Gareau","year":"2011","unstructured":"Gareau C, Fournier MJ, Filion C, Coudert L, Martel D, Labelle Y, Mazroui R (2011) p21 (WAF1\/CIP1) upregulation through the stress granule-associated protein CUGBP1 confers resistance to bortezomib-mediated apoptosis. PLoS ONE 6:e20254","journal-title":"PLoS ONE"},{"key":"2643_CR15","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1038\/onc.2009.257","volume":"28","author":"A Seckinger","year":"2009","unstructured":"Seckinger A, Meissner T, Moreaux J, Goldschmidt H, Fuhler GM, Benner A, Hundemer M, R\u00e8me T, Shaughnessy JD Jr, Barlogie B, Bertsch U, Hillengass J, Ho AD, Pantesco V, Jauch A, De Vos J, Rossi JF, M\u00f6hler T, Klein B, Hose D (2009) Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene 28:3866\u20133879","journal-title":"Oncogene"},{"key":"2643_CR16","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1200\/JCO.2012.48.4923","volume":"31","author":"K Neben","year":"2013","unstructured":"Neben K, Jauch A, Hielscher T, Hillengass J, Lehners N, Seckinger A, Granzow M, Raab MS, Ho AD, Goldschmidt H, Hose D (2013) Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol 31:4325\u20134332","journal-title":"J Clin Oncol"},{"key":"2643_CR17","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.1989.7.4.415","volume":"7","author":"WS Dalton","year":"1989","unstructured":"Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BG, Taylor CW, Miller TP, Salmon SE (1989) Drug-resistance in multiple myeloma and non-Hodgkin\u2019s lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7:415\u2013424","journal-title":"J Clin Oncol"},{"key":"2643_CR18","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1124\/jpet.111.187542","volume":"341","author":"SE Verbrugge","year":"2012","unstructured":"Verbrugge SE, Assaraf YG, Dijkmans BA, Scheffer GL, Al M, den Uyl D, Oerlemans R, Chan ET, Kirk CJ, Peters GJ, van der Heijden JW, de Gruijl TD, Scheper RJ, Jansen G (2012) Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein\/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis. J Pharmacol Exp Ther 341:174\u2013182","journal-title":"J Pharmacol Exp Ther"},{"key":"2643_CR19","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1751-553X.2011.01384.x","volume":"34","author":"B Zheng","year":"2012","unstructured":"Zheng B, Zhou R, Gong Y, Yang X, Shan Q (2012) Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines. Int J Lab Hematol 34:237\u2013247","journal-title":"Int J Lab Hematol"},{"key":"2643_CR20","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00280-006-0367-6","volume":"60","author":"H Minderman","year":"2007","unstructured":"Minderman H, Zhou Y, O\u2019Loughlin KL, Baer MR (2007) Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status. Cancer Chemother Pharmacol 60:245\u2013255","journal-title":"Cancer Chemother Pharmacol"},{"key":"2643_CR21","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1111\/j.1751-553X.2009.01145.x","volume":"32","author":"S L\u00fc","year":"2010","unstructured":"L\u00fc S, Chen Z, Yang J, Chen L, Zhou H, Xu X, Li J, Han F, Wang J (2010) The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562\/A02. Int J Lab Hematol 32:e123\u2013e131","journal-title":"Int J Lab Hematol"},{"key":"2643_CR22","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.bbrc.2007.07.049","volume":"361","author":"H Rumpold","year":"2007","unstructured":"Rumpold H, Salvador C, Wolf AM, Tilg H, Gastl G, Wolf D (2007) Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors. Biochem Biophys Res Commun 361:549\u2013554","journal-title":"Biochem Biophys Res Commun"},{"key":"2643_CR23","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s00280-013-2136-7","volume":"71","author":"R O\u2019Connor","year":"2013","unstructured":"O\u2019Connor R, Ooi MG, Meiller J, Jakubikova J, Klippel S, Delmore J, Richardson P, Anderson K, Clynes M, Mitsiades CS, O\u2019Gorman P (2013) The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias. Cancer Chemother Pharmacol 71:1357\u20131368","journal-title":"Cancer Chemother Pharmacol"},{"key":"2643_CR24","first-page":"803","volume":"31","author":"T Nakamura","year":"2007","unstructured":"Nakamura T, Tanaka K, Matsunobu T, Okada T, Nakatani F, Sakimura R, Hanada M, Iwamoto Y (2007) The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing\u2019s family tumor cells. Int J Oncol 31:803\u2013811","journal-title":"Int J Oncol"},{"key":"2643_CR25","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1182\/blood-2012-03-415588","volume":"120","author":"A Seckinger","year":"2012","unstructured":"Seckinger A, Meissner T, Moreaux J, Depeweg D, Hillengass J, Hose K, R\u00e8me T, R\u00f6sen-Wolff A, Jauch A, Schnettler R, Ewerbeck V, Goldschmidt H, Klein B, Hose D (2012) Clinical and prognostic role of annexin A2 in multiple myeloma. Blood 120:1087\u20131094","journal-title":"Blood"},{"key":"2643_CR26","doi-asserted-by":"crossref","first-page":"570","DOI":"10.2174\/138920111795164048","volume":"12","author":"AK Tiwari","year":"2011","unstructured":"Tiwari AK, Sodani K, Dai CL, Ashby CR Jr, Chen ZS (2011) Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol 12:570\u2013594","journal-title":"Curr Pharm Biotechnol"},{"key":"2643_CR27","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.chroma.2014.04.024","volume":"1345","author":"J Clemens","year":"2014","unstructured":"Clemens J, Longo M, Seckinger A, Hose D, Haefeli WE, Weiss J, Burhenne J (2014) Stability of the proteasome inhibitor bortezomib in cell based assays determined by ultra-high performance liquid chromatography coupled to tandem mass spectrometry. J Chromatogr A 1345:128\u2013138","journal-title":"J Chromatogr A"},{"key":"2643_CR28","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/jhep.2002.34133","volume":"36","author":"SR Vavricka","year":"2002","unstructured":"Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K (2002) Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36:164\u2013172","journal-title":"Hepatology"},{"key":"2643_CR29","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1093\/jac\/dkq324","volume":"65","author":"SK K\u00f6nig","year":"2010","unstructured":"K\u00f6nig SK, Herzog M, Theile D, Zembruski N, Haefeli WE, Weiss J (2010) Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J Antimicrob Chemother 65:2319\u20132328","journal-title":"J Antimicrob Chemother"},{"key":"2643_CR30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00210-005-0022-5","volume":"372","author":"T Peters","year":"2006","unstructured":"Peters T, Lindenmaier H, Haefeli WE, Weiss J (2006) Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 372:291\u2013299","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2643_CR31","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/jac\/dkq501","volume":"66","author":"NC Zembruski","year":"2011","unstructured":"Zembruski NC, B\u00fcchel G, J\u00f6dicke L, Herzog M, Haefeli WE, Weiss J (2011) Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro. J Antimicrob Chemother 66:802\u2013812","journal-title":"J Antimicrob Chemother"},{"key":"2643_CR32","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","volume":"53","author":"MM Gottesman","year":"2002","unstructured":"Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53:615\u2013627","journal-title":"Annu Rev Med"},{"key":"2643_CR33","unstructured":"Pharmacology review part 1 (p. 8), drug approval package of bortezomib, Center of Drug Evaluation and Research, Food and Drug Association (FDA), c2003 [cited 2014 August 5]. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2003\/21602_Velcade_pharmr_P1.pdf"},{"key":"2643_CR34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.chembiol.2012.01.003","volume":"19","author":"AF Kisselev","year":"2012","unstructured":"Kisselev AF, van der Linden WA, Overkleeft HS (2012) Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol 19:99\u2013115","journal-title":"Chem Biol"},{"key":"2643_CR35","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1515\/hsz-2012-0212","volume":"393","author":"P Beck","year":"2012","unstructured":"Beck P, Dubiella C, Groll M (2012) Covalent and non-covalent reversible proteasome inhibition. Biol Chem 393:1101\u20131120","journal-title":"Biol Chem"},{"key":"2643_CR36","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1385\/MO:19:2:87","volume":"19","author":"H Schwarzenbach","year":"2002","unstructured":"Schwarzenbach H (2002) Expression of MDR1\/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma. Med Oncol 19:87\u2013104","journal-title":"Med Oncol"},{"key":"2643_CR37","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.bcp.2011.10.009","volume":"83","author":"LH Wilt de","year":"2012","unstructured":"de Wilt LH, Jansen G, Assaraf YG, van Meerloo J, Cloos J, Schimmer AD, Chan ET, Kirk CJ, Peters GJ, Kruyt FA (2012) Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer. Biochem Pharmacol 83:207\u2013217","journal-title":"Biochem Pharmacol"},{"key":"2643_CR38","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/cncr.23224","volume":"112","author":"A Busse","year":"2008","unstructured":"Busse A, Kraus M, Na IK, Rietz A, Scheibenbogen C, Driessen C, Blau IW, Thiel E, Keilholz U (2008) Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits. Cancer 112:659\u2013670","journal-title":"Cancer"},{"key":"2643_CR39","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2141.2006.06132.x","volume":"134","author":"R Shringarpure","year":"2006","unstructured":"Shringarpure R, Catley L, Bhole D, Burger R, Podar K, Tai YT, Kessler B, Galardy P, Ploegh H, Tassone P, Hideshima T, Mitsiades C, Munshi NC, Chauhan D, Anderson KC (2006) Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol 134:145\u2013156","journal-title":"Br J Haematol"},{"key":"2643_CR40","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s40262-012-0010-0","volume":"51","author":"P Moreau","year":"2012","unstructured":"Moreau P, Karamanesht II, Domnikova N, Kyselyova MY, Vilchevska KV, Doronin VA, Schmidt A, Hulin C, Leleu X, Esseltine DL, Venkatakrishnan K, Skee D, Feng H, Girgis S, Cakana A, van de Velde H, Deraedt W, Facon T (2012) Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. Clin Pharmacokinet 51:823\u2013829","journal-title":"Clin Pharmacokinet"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2643-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2643-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2643-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,18]],"date-time":"2019-08-18T00:21:03Z","timestamp":1566087663000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2643-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,5]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["2643"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2643-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,5]]}}}